AMS:HEIA 12 February 2026 - 23 April 2026

April 23, 2026, 10:39 AM EDT. ARS Pharmaceuticals shares surged 7.1% to $8.40 on higher investor interest following FDA approval of expanded use for its lead product, neffy. The drop in minimum age restrictions allows its use in children and adults weighing at least 33 lbs for severe allergic reactions. The company anticipates a quarterly loss of 50 cents per share, improving 42.9% year-over-year, with revenues expected to increase 180.4% to $22.35 million. Earnings estimate revisions have been positive, with a 4.6% rise in the past month, often a signal of short-term price gains. ARS carries a Zacks Rank #3 (Hold). Aurinia Pharmaceuticals, a peer in the medical-drugs sector, also rose 3.8% recently amid improving earnings forecasts.